BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $416 | +59.4% | 15,775 | +3.8% | 0.00% | +100.0% |
| Q2 2023 | $261 | +18.6% | 15,199 | +14.3% | 0.00% | 0.0% |
| Q1 2023 | $220 | +86.4% | 13,298 | -14.1% | 0.00% | +100.0% |
| Q4 2022 | $118 | -99.9% | 15,476 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $154,000 | +10.8% | 15,476 | +1.1% | 0.00% | 0.0% |
| Q2 2022 | $139,000 | -13.1% | 15,311 | -3.1% | 0.00% | 0.0% |
| Q1 2022 | $160,000 | -72.1% | 15,794 | -54.1% | 0.00% | -50.0% |
| Q4 2021 | $574,000 | -29.9% | 34,384 | +96.7% | 0.00% | -71.4% |
| Q3 2021 | $819,000 | -27.8% | 17,477 | -6.1% | 0.01% | -22.2% |
| Q2 2021 | $1,134,000 | +37.5% | 18,610 | +39.0% | 0.01% | -71.0% |
| Q1 2021 | $825,000 | +2.0% | 13,393 | +17.7% | 0.03% | 0.0% |
| Q4 2020 | $809,000 | +90.4% | 11,382 | +0.5% | 0.03% | +72.2% |
| Q3 2020 | $425,000 | +11.8% | 11,325 | -2.9% | 0.02% | 0.0% |
| Q2 2020 | $380,000 | +0.5% | 11,658 | -10.6% | 0.02% | +100.0% |
| Q1 2020 | $378,000 | – | 13,039 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |